The value of pharmacogenetic markers for personalized approach to the statins treatment

Abstract

This review presents the most studied genetic markers which are risk factors for adverse drug reactions in patients who are treated with statins and/or associated with resistance to them. We have considered the possible practical advice for individual therapy with statins in patients with a known genotype. Identification of the gene variant SLCO1B1*5 is a risk factor for myopathy and rhabdomyolysis and HMGCR gene haplotype H7 is associated with less reduction in LDL cholesterol in patients receiving statins. Pathological effect of a particular genetic marker is modified by statin class or calculated personal dose. The use of pharmacogenetic testing will reduce the frequency of adverse outcomes of statins and make a prediction their performance in a specific patient. Howeverfurther studies on the translation of these personalized medicine tests to clinical practice are needed.

Keywords

• slco1b1*5
• hmgcr
• hmg-coa reductase inhibitors
• myopathy
• slco1b1*5
• hmgcr